3月26日 - ** 医疗技术公司 Firefly Neuroscience AIFF.O 股价盘前上涨 24.99% 至 2.10 美元
** 该公司称已与美国战争部建立合作关系，与美国军事健康项目挂钩
** 称其通过美国食品及药物管理局（FDA）认证的脑部扫描技术将用于帮助评估和治疗现役军人和退伍军人的创伤后应激障碍和创伤性脑损伤
** 称该技术可为医疗服务提供商提供脑部数据，帮助诊断、制定治疗计划和跟踪病人的进展情况
** 补充说，该合作关系将其商业触角扩展到了美国政府和国防卫生部门
** 合作关系和相关计划的具体细节仍然保密 - AIFF
** 2025年，AIFF股价下跌超过66%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.